XENETIC BIOSCIENCES INC (XBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.86-7.21%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · XBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -84.5% |
| Our one-year growth estimate | diamond | -20.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 63.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
XBIO — divestiture
Dated 2026-09-16
Entry into a Material Definitive Agreement. Share Exchange Agreement On September 14, 2026, Xenetic Biosciences, Inc., a Nevada corporation (“Xenetic” or the “Company”), entered into a Share Exchange Agreement (the “Exchange Agreement”) with Santersus AG, a Swiss corporation ( Aktiengesellschaft ) (“Santersus”), the sellers listed on Schedule I thereto (each, a “Seller,” and collectively with the holders of Santersus securities who subsequently become parties to the Exchange Agreement, the “S…
Why it matters: The deal would add Santersus's NucleoCapture program to Xenetic's DNase platform. A failed vote could block the planned combination.
Watch forA filed vote result shows Xenetic shareholders approved the share swap. All required closing steps are complete.
Also watch forShareholders reject the deal, or a required closing condition fails and the swap ends.
Why it matters: The August report showed $6.5 million in cash and $0.7 million in quarterly royalties. The next report can show whether funding and royalty income keep pace with work.
Watch forThe report shows cash above $6.5 million and royalty revenue at or above $0.7 million for the quarter.
Also watch forThe report shows cash below $6.5 million or quarterly royalties below $0.7 million.
Why it matters: Closing would set the combined company's ownership and cash position. A delay or changed terms could alter its plans.
Watch forA closing filing confirms the swap, the final share ratio, and the combined company's cash.
Also watch forA filing reports a delay, a changed share ratio, unmet conditions, or the deal's end.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$285 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $716 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,317 loss on $10,000 · 63.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.